Pediatric Hematology and Oncology Department, Hôpital pour Enfant de La Timone, AP-HM, Marseille, France; Centre de Recherche en Cancérologie de Marseille Inserm U1068, Aix-Marseille University, Marseille, France; Metronomics Global Health Initiative, Marseille, France.
SIREDO Oncology Center (Care, Innovation and Research for Children, Adolescents and Young Adults with Cancer), Institut Curie, PSL University, Paris, France.
Trends Cancer. 2020 Oct;6(10):819-828. doi: 10.1016/j.trecan.2020.05.007. Epub 2020 Jun 26.
Maintenance therapy sometimes relies on the use of metronomic chemotherapy (MC); that is, the continuous administration of low-dose chemotherapy. Maintenance therapy has been successfully used for decades in pediatric patients with acute lymphoblastic leukemia (ALL) and recent results have demonstrated improved outcomes in patients with pediatric high-risk rhabdomyosarcoma (RMS) on maintenance therapy. Here, we review the use of metronomic maintenance therapy in pediatric cancer and discuss its mechanisms of action on the tumor microenvironment and cancer cells. We also discuss its potential use as a chemotherapy alone or in combination with targeted therapies, immunotherapies, or agents for drug repurposing.
维持治疗有时依赖于节拍化疗（MC）的使用，即低剂量化疗的连续给药。维持治疗已成功应用于数十年的儿科急性淋巴细胞白血病（ALL）患者，最近的结果表明，在接受维持治疗的儿科高危横纹肌肉瘤（RMS）患者中，其疗效得到了改善。在这里，我们回顾了节拍维持治疗在儿科癌症中的应用，并讨论了其对肿瘤微环境和癌细胞的作用机制。我们还讨论了其单独作为化疗药物，或与靶向治疗、免疫疗法或药物重定位药物联合使用的潜在用途。
